Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sitryx launches with $30m funding to develop disease-modifying therapeutics
New biopharmaceutical company Sitryx has been launched with $30m fundraising for the development of disease modifying therapeutics in immunometabolism.
Research & Development
-
08 Oct 2018
-
05 Oct 2018
Arrowhead, Janssen sign $3.7bn license and collaboration deal
Biopharmaceutical firm Arrowhead Pharmaceuticals has signed a license and collaboration agreement with Janssen Pharmaceuticals for the development and commercialization of hepatitis B virus (HBV) treatment, ARO-HBV.
-
04 Oct 2018
Boston Pharmaceuticals buys Novartis’ three anti-infective drug candidates
Boston Pharmaceuticals has signed a licensing and equity agreement with Novartis for the worldwide rights to three of the latter's anti-infective candidates for the potential treatment of Gram-negative infections.
-
03 Oct 2018
Kite, HiFiBiO to develop technology for discovery of neoantigen-reactive TCRs to treat cancer
Gilead firm Kite and HiFiBiO Therapeutics have entered into a research collaboration and license agreement to develop technology for the discovery of neoantigen-reactive T cell receptors (TCRs) to treat various cancers such as solid tumors.
-
03 Oct 2018
Kala Pharmaceuticals raises $110m financing to achieve significant milestones
Us biopharma company Kala Pharmaceuticals has closed a $110m credit facility with funds managed by healthcare focused investment firm Athyrium Capital Management.
-
03 Oct 2018
Cancer startup GO Therapeutics signs $195m licensing deal with Roche
GO Therapeutics has signed a license agreement with Roche for new glycotargeting bispecific cancer treatment.
-
01 Oct 2018
KSQ Therapeutics raises $80m financing to advance oncology drug candidates
KSQ Therapeutics has secured $80m series C financing to advance oncology drug candidates generated from its CRISPRomics drug discovery engine into clinical studies.
-
28 Sep 2018
Janssen terminates cancer drug development deal with Geron
Janssen Biotech has ceased the collaboration and license agreement (CLA) with biopharmaceutical firm Geron for experimental cancer drug imetelstat.
-
27 Sep 2018
Kanwa to acquire Midatech Pharma US
Midatech Pharma has agreed to sell Midatech Pharma US to Kanwa Holdings, an investment vehicle affiliated with Barings, for total consideration of up to $19m.
-
27 Sep 2018
Alexion to buy Syntimmune in $1.2bn deal
Alexion Pharmaceuticals has agreed to acquire US-based clinical-stage biotechnology firm Syntimmune in a deal valued at around $1.2bn.